Braxia Scientific (Braxia Scientific) Common Stock : $74.86 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Braxia Scientific Common Stock?

Braxia Scientific's quarterly common stock declined from Jun. 2023 ($75.59 Mil) to Sep. 2023 ($74.22 Mil) but then increased from Sep. 2023 ($74.22 Mil) to Dec. 2023 ($74.86 Mil).

Braxia Scientific's annual common stock increased from Mar. 2021 ($74.77 Mil) to Mar. 2022 ($76.57 Mil) but then declined from Mar. 2022 ($76.57 Mil) to Mar. 2023 ($73.40 Mil).

Braxia Scientific Common Stock Historical Data

The historical data trend for Braxia Scientific's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Braxia Scientific Common Stock Chart

Braxia Scientific Annual Data

Trend

Mar21

Mar22

Mar23

Common Stock

74.77

76.57

73.40

Braxia Scientific Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial												72.99	73.40	75.59	74.22	74.86

Braxia Scientific Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Braxia Scientific (Braxia Scientific) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Braxia Scientific Corp (OTCPK:BRAXF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

4960:Germany 4960:Germany BRAX:Canada

Address

700 Bay Street, Suite 1903, Toronto, ON, CAN, M5G 1Z6

Website

https://www.braxiascientific.com

Braxia Scientific Corp is a research-driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as depressive disorder among others. It is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. The company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.